MarketVIEW Travel Vaccines  ·  for order only

Tick-borne Encephalitis (TBE)
Vaccines Forecast

Tick-borne encephalitis virus is a flavivirus transmitted by infected Ixodes ticks across a vast endemic belt running from central and eastern Europe, through Russia, to the islands of northern Japan. Reported TBE incidence has been rising, and the endemic footprint expanding, across Europe since 2017, driven in part by climate-linked changes in tick habitat and activity, yet Encepur (Bavarian Nordic) and FSME-IMMUN, marketed in the US as TicoVac (Pfizer), remain the only licensed vaccines worldwide. This is a comprehensive, endemic-market commercial assessment of the TBE vaccine opportunity to 2035, drawing on VacZine Analytics' long standing, independent authority in travel disease vaccine markets.

Endemic Belt: C&E Europe to N. Japan Incidence Rising & Spreading Since 2017 Encepur & FSME-IMMUN/TicoVac Only Options Endemic-Market Forecast to 2035
Product catalogue
VAMV022
For order only

Format
Executive presentation + Excel model
Coverage
Endemic European/Eurasian markets
Indications
TBE prevention, endemic & traveler
Forecast horizon
To 2035
Approach
Value ($m)/volume (mio doses) model
Base edition
For order only
Availability
Syndicated / bespoke
3,650
TBE cases reported across 20
EU/EEA countries in 2022, up 14%
2017
Year reported TBE incidence began
its still-continuing rise in Europe
<2%
Case-fatality rate for the
predominant European TBEV subtype
2
Licensed TBE vaccines worldwide:
Encepur & FSME-IMMUN/TicoVac
Disease background

A rising, spreading flavivirus with only decades-old vaccines to meet it

This review sets out TBE virology and transmission, its clinical spectrum, and the latest epidemiological evidence for a disease whose incidence and geographic footprint are both moving in the wrong direction.

ECDC 2022 surveillance data & 2025/26 season update

Pathogen overview - Tick-borne encephalitis virus (TBEV)

Tick-borne encephalitis virus (TBEV) is a flavivirus in the same family as yellow fever, Japanese encephalitis and dengue viruses. It is transmitted to humans principally through the bite of infected Ixodes ticks, Ixodes ricinus across central and western Europe and Ixodes persulcatus further east, which acquire and maintain the virus in a natural cycle involving small rodents and other wild mammals. Three main TBEV subtypes are recognised, European, Siberian and Far Eastern, and they differ meaningfully in severity: the European subtype carries a case-fatality rate of under 2%, the Siberian subtype around 6-8% with a recognised risk of chronic, slowly progressive encephalitis in children, and the Far Eastern subtype 20-40% among those with neurological disease.

Most TBEV infections are mild or asymptomatic, but a substantial minority progress to neuroinvasive disease, meningitis, meningoencephalitis, encephalomyelitis and paralytic forms resembling poliomyelitis. Among patients with European-subtype neuroinvasive disease, an estimated 20-40% (with some series reporting up to 40-50%) go on to experience long-term or permanent sequelae, including limb paresis or paralysis in up to around 10% of cases and neuropsychiatric after-effects, persistent cognitive, mood or sleep-wake disturbance, in a further 10-20%. There is no specific antiviral treatment; management is supportive, which is precisely why vaccination, rather than post-exposure treatment, sits at the centre of TBE control policy in endemic countries.

ECDC surveillance confirms that after a broadly stable long-term trend, reported TBE incidence across the EU/EEA has been on a gradual, sustained rise since 2017. In 2022, the most recent full annual total available, 20 EU/EEA countries reported 3,650 TBE cases (96.3% laboratory-confirmed), an EU/EEA notification rate of 0.81 per 100,000, up 14% on 2021's rate of 0.71 per 100,000 across 25 reporting countries. ECDC's most recent country-level notification-rate release, covering 2019 to 2023, was published in March 2025, and preliminary assessments of the 2024 season across multiple endemic countries point to a continued high disease burden, with several countries at risk of new peaks once late notifications are finalised. The prevailing scientific view links this rise substantially to climate-driven changes in tick habitat and activity: milder winters, longer tick-activity seasons and the documented northward and altitudinal expansion of Ixodes persulcatus and I. ricinus habitat are extending TBE risk into previously non-endemic or marginal areas of central, northern and eastern Europe.

TBEV's endemic range spans a broad Eurasian forest belt running from eastern France, Germany, Austria, Switzerland and the Baltic states, across central and Eastern Europe, Russia and Kazakhstan, to China, the Russian Far East and the northern Japanese island of Hokkaido. Highest-incidence countries have traditionally included the Baltic states, the Czech Republic, Slovenia and parts of Austria, Germany and Scandinavia, but ECDC and academic surveillance both describe a widening, rather than a static, endemic footprint, an important structural consideration for any vaccine demand model built for this market.

2026 3,650 EU/EEA cases in 2022, up 14% YoY  |  incidence rising since 2017  |  <2% CFR (European subtype), up to 40% Far Eastern  |  Encepur & FSME-IMMUN/TicoVac remain the only licensed options  |  no next-gen candidate yet in clinical development
Product & competitor landscape

Two long-standing vaccines, a widening market, and early-stage research beyond them

The TBE vaccine market has been a stable, two-player field for decades. That stability now sits against a backdrop of rising, geographically expanding demand, and the first early academic moves toward a broader-coverage, next-generation alternative.

  • Bavarian NordicLicensed, endemic Europe
    Encepur Inactivated whole-virus vaccine
    Bavarian Nordic has marketed Encepur across endemic European markets since acquiring it from GSK (previously Novartis/Chiron) in October 2019. A revised Encepur SmPC took effect in Germany in May 2025, extending the approved booster interval and refining the vaccine's rapid "Express" three-dose priming schedule, in which all three primary doses are given within 21 days.
  • PfizerLicensed, Europe & US
    FSME-IMMUN / TicoVac Inactivated whole-virus vaccine
    Pfizer (previously Baxter) markets FSME-IMMUN across endemic European markets and, under the brand TicoVac, in the United States, where the FDA approved it in August 2021 for use from age 1 upward, the only FDA-approved TBE vaccine and the sole option specifically labelled for US travelers to, and residents of, endemic areas.
  • Russian & CIS manufacturersLicensed, Russia/CIS
    Domestic Russian TBE vaccines
    Local Russian manufacturers continue to produce inactivated TBE vaccines for the Russian and wider CIS market, reflecting the country's own substantial TBE burden across its Siberian and Far Eastern endemic regions.
  • Academic & biotech research groupsPreclinical, mRNA-based
    Next-generation mRNA-LNP candidates
    Multiple academic groups have begun evaluating mRNA-LNP TBE vaccine candidates in animal models, aiming to overcome first-generation inactivated vaccines' comparatively limited cross-protection against heterologous TBEV strains. As of early 2026 these programmes remain at the preclinical stage, with no candidate yet in clinical development.
  • ECDC & national surveillance bodiesActive surveillance
    Seasonal TBE notification & range monitoring
    ECDC and national public health institutes across endemic countries continue to track TBE notification rates and geographic spread season by season, the primary real-world signal of the disease's continuing, climate-linked expansion.
Field inflection point
Still 2 vaccines

Two inactivated whole-virus vaccines, essentially unchanged in mechanism for decades, remain the entirety of the licensed TBE vaccine market, even as reported incidence keeps climbing and the endemic footprint keeps widening. Early-stage mRNA-based research offers a longer-term route to broader cross-strain protection, but no next-generation candidate has yet reached clinical testing. That combination, a stable competitive landscape set against steadily rising, geographically expanding demand, materially shapes the near-term commercial forecast this report is built to quantify.

Scope of analysis

Six analytical layers - one commercial picture

This is a genuinely comprehensive report with a wide endemic-market focus, spanning disease burden, the vaccine competitive landscape, target product profile design and scenario-based demand forecasting to 2035.

Endemic-market demand forecast

Value ($m) and volume (mio doses) demand modelling to 2035 across endemic European and Eurasian markets, by country.

Competitor & pipeline review

Full review of Encepur, FSME-IMMUN/TicoVac, Russian-manufactured vaccines and early-stage next-generation mRNA research.

Target product profile

Ideal target product profile assessment for both existing inactivated vaccines and any future broader-coverage candidate.

Scenario-based revenue forecasts

Volume and value forecasts to 2035, reflecting alternative disease-incidence and market-upside scenarios.

Disease burden & epidemiology

Full epidemiological review, incidence rising since 2017 and the climate-driven expansion of the endemic footprint.

Early decision-making support

Designed as an ideal tool to aid decision making in TBE vaccine market entry, access strategy and investment planning.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the indication and geography framework. Full volume/value outputs, pricing assumptions and country-level data are in the licensed model.

Indication / segmentGeographyTarget groupVaccine statusRevenue scenario
TBE prevention - general populationBaltic states & Central EuropeOccupational / rural at-risk adultsLicensed (Encepur / FSME-IMMUN)Modelled
TBE prevention - travelersNon-endemic source marketsInternational & domestic travelersLicensed (FSME-IMMUN/TicoVac)Modelled
TBE prevention - paediatricEndemic Central/Eastern EuropeChildren aged 1 and aboveLicensedModelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - baseAll endemic geographiesAll groupsAll scenarios$███m
Full model in the licensed workbook
Endemic European/Eurasian markets · to 2035 · all TBE indications
Register interest →
Deliverables

What you receive

A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for organisations evaluating the TBE vaccine opportunity across endemic European and Eurasian markets.

  • Executive presentation (PDF) - disease background, epidemiology, vaccine landscape and full commercial assessment with supporting narrative and references
  • MS-Excel value/volume forecast model - demand outputs to 2035 across all relevant country markets and target groups
  • Endemic-market coverage - country-level modelling across the Eurasian endemic belt from Central Europe to the Russian Far East
  • Competitor intelligence - Encepur (Bavarian Nordic), FSME-IMMUN/TicoVac (Pfizer), Russian-manufactured vaccines and next-generation mRNA research
  • Updated epidemiology module - ECDC surveillance data through 2022/23 and the climate-driven, geographically expanding incidence trend
  • Early decision-making support - target product profile and market entry strategy guidance for TBE vaccine planning
Target audience

Built for organisations evaluating the TBE vaccine opportunity

Most valuable to teams assessing the tick-borne encephalitis vaccine market against their own pipeline, BD ambitions or investment thesis, drawing on VacZine Analytics' long standing expertise in travel diseases.

Vaccine developers

Positioning, target product profile and commercial feasibility assessment for existing and any future TBE candidates.

Corporate strategy & BD

Validate the size and trajectory of an endemic market where demand is rising even as the competitive field stays stable.

Investors & analysts

Independent assessment of market structure and commercial upside for due diligence on TBE and wider travel vaccine entrants.

Public health & immunisation programmes

Demand modelling to support at-risk population and traveler vaccination programme planning in endemic and near-endemic regions.

Researchers & academia

Comprehensive epidemiology and R&D landscape review to support grant, translational and next-generation vaccine planning.

Market access & policy

Pricing benchmarks and access-pathway assumptions across public immunisation and private traveler-health channels.

About this analysis · VAMV022

VacZine Analytics has long standing expertise in travel diseases, positioning us to track the tick-borne encephalitis vaccine market's slower-moving supply side against its faster-moving epidemiological trend. This is a genuinely comprehensive analysis with a wide endemic-market focus, spanning the full Eurasian TBE belt from Central Europe to the Russian Far East, and it has been well received by clients in the field for the depth of its epidemiological review and its country-level demand modelling. Few groups have followed this market as closely for as long, and that recognised, independent expertise underpins everything in the analysis.

This report is currently available for order only; no syndicated edition has yet been published. A first syndicated MarketVIEW edition would incorporate the latest ECDC surveillance data, the continuing rise and geographic expansion of TBE incidence since 2017, and the current status of Encepur and FSME-IMMUN/TicoVac, the field's only two licensed vaccines. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV022 · Syndicated & bespoke

Syndicate the refresh - or commission the answer you need

Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc TBE vaccine analysis, a briefing call is included on request.